Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.

doi:10.1111/bjh.14547

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.

British journal of haematology - 1 Mar 2017

Maciocia Nicola, Melville Andrew, Cheesman Simon, Sharpley Faye, Ramasamy Karthik, Streetly Matthew, Jenner Matthew, Benjamin Reuben, Schey Steve, Maciocia Paul, Popat Rakesh, D'sa Shirley, Rismani Ali, Cerner Aviva, Yong Kwee, Rabin Neil

Abstract excerpt

Myeloma patients who become refractory to immunomodulatory agents (IMiDs) and bortezomib have poor survival, with limited therapeutic options. Pomalidomide has shown improved survival and good tolerability in this patient cohort in clinical trials, but real world data are scarce. We retrospectively analysed all patients treated with pomalidomide at five UK centres between 2013 and 2016. Of 85 patients identified,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dexamethasone

Share to Kidney Function Tests

Share to Multiple Myeloma

Share to Recurrence

Share to Renal Insufficiency

Share to Retreatment

Share to Thalidomide

Source

Open in PubMed

Identifiers

PMID: 28211054
DOI: 10.1111/bjh.14547

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.PMID 28211054Read ↗

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodySemantic proximity Read ↗

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment responseSemantic proximity Read ↗

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalitiesSemantic proximity Read ↗

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaSemantic proximity Read ↗

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial resultsSemantic proximity Read ↗

Pattern of Use and Efficacy of Daratumumab-based Therapy in Patients With Multiple Myeloma in a Real-world Setting: a Single Institution ExperienceSemantic proximity Read ↗

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trialSemantic proximity Read ↗

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaSemantic proximity Read ↗

Myeloma Is Not a Single Disease.Semantic proximity Read ↗

Molecular mechanisms in multiple myeloma drug resistance.Semantic proximity Read ↗

Ultra high-risk myeloma.Semantic proximity Read ↗

Applications of Multiparameter Flow Cytometry in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.